



OssDsign strengthens its commercial footprint in the Western U.S. through new agreement with IDN

Uppsala, Sweden, December 5, 2025. OssDsign AB (publ.) today announces that the company has signed an agreement with an IDN (Integrated Delivery Network) in the Western U.S. marking the company's most significant opportunity for sales growth in the region to date.

The agreement allows IDN member hospitals and clinics, at their discretion, to take advantage of special pricing and pre-negotiated terms for OssDsign's nanosynthetic bone graft OssDsign Catalyst®. Since entering the orthobiologics business late 2021, the company has had a natural gravity towards the Eastern U.S.; however, during 2025 OssDsign has increasingly been building its commercial footprint in the Western U.S. culminating in this agreement which represents the company's most significant opportunity for sales growth in the region to date.

"We are very pleased to have secured this vital agreement which represents a large commercial opportunity for us, and we will continue to expand our commercial footprint in the Western U.S. This new contract win is a direct result of the strong clinical peer-reviewed PROPEL data showing 88.4% fusion rate in a challenging patient cohort as well as the preclinical Ovine results published earlier this year. It is clear that OssDsign Catalyst's differentiation and strong clinical outcomes is giving us critical leverage," said Morten Henneveld, CEO of OssDsign.

About OssDsign Catalyst®

OssDsign Catalyst is a nanosynthetic bone graft that shows rapid and robust bone formation, even in poorly vascularized environments. OssDsign Catalyst's patented nanocrystalline structure and incorporated silicate ions, which mimic the body's natural bone, enable bone formation in the centre of the fusion mass. OssDsign Catalyst is designed to deliver a decreased non-union risk, making it highly applicable for both simple and complex patients.

For further information, please contact:

Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdesign.com

Certified Adviser

The Company's Certified Adviser is Carnegie Investment Bank AB (publ)

About OssDsign

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's

share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.